nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—Niacin—atherosclerosis	0.118	0.169	CbGbCtD
Vilazodone—CYP2D6—Simvastatin—atherosclerosis	0.0933	0.134	CbGbCtD
Vilazodone—CYP2D6—Pravastatin—atherosclerosis	0.0913	0.131	CbGbCtD
Vilazodone—CYP2D6—Lovastatin—atherosclerosis	0.0913	0.131	CbGbCtD
Vilazodone—CYP3A4—Rosuvastatin—atherosclerosis	0.0638	0.0916	CbGbCtD
Vilazodone—CYP3A4—Ezetimibe—atherosclerosis	0.0638	0.0916	CbGbCtD
Vilazodone—CYP3A4—Simvastatin—atherosclerosis	0.0593	0.0851	CbGbCtD
Vilazodone—CYP3A4—Pravastatin—atherosclerosis	0.0581	0.0833	CbGbCtD
Vilazodone—CYP3A4—Lovastatin—atherosclerosis	0.0581	0.0833	CbGbCtD
Vilazodone—Sexual dysfunction—Simvastatin—atherosclerosis	0.00701	0.0343	CcSEcCtD
Vilazodone—Sexual dysfunction—Pravastatin—atherosclerosis	0.00633	0.031	CcSEcCtD
Vilazodone—Cataract—Lovastatin—atherosclerosis	0.00441	0.0216	CcSEcCtD
Vilazodone—Cataract—Simvastatin—atherosclerosis	0.00413	0.0202	CcSEcCtD
Vilazodone—Gastroenteritis—Rosuvastatin—atherosclerosis	0.00406	0.0199	CcSEcCtD
Vilazodone—Cataract—Pravastatin—atherosclerosis	0.00373	0.0183	CcSEcCtD
Vilazodone—Aripiprazole—HRH1—atherosclerosis	0.00355	0.501	CrCbGaD
Vilazodone—Trazodone—HRH1—atherosclerosis	0.00354	0.499	CrCbGaD
Vilazodone—Breast disorder—Rosuvastatin—atherosclerosis	0.00325	0.0159	CcSEcCtD
Vilazodone—Breast disorder—Ezetimibe—atherosclerosis	0.0027	0.0132	CcSEcCtD
Vilazodone—Disturbance in sexual arousal—Niacin—atherosclerosis	0.0026	0.0127	CcSEcCtD
Vilazodone—Migraine—Niacin—atherosclerosis	0.00258	0.0126	CcSEcCtD
Vilazodone—Erectile dysfunction—Lovastatin—atherosclerosis	0.00243	0.0119	CcSEcCtD
Vilazodone—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00238	0.0117	CcSEcCtD
Vilazodone—Erectile dysfunction—Simvastatin—atherosclerosis	0.00227	0.0111	CcSEcCtD
Vilazodone—Mental disorder—Rosuvastatin—atherosclerosis	0.00218	0.0107	CcSEcCtD
Vilazodone—Flatulence—Rosuvastatin—atherosclerosis	0.00213	0.0105	CcSEcCtD
Vilazodone—Erectile dysfunction—Niacin—atherosclerosis	0.00208	0.0102	CcSEcCtD
Vilazodone—Erectile dysfunction—Pravastatin—atherosclerosis	0.00205	0.0101	CcSEcCtD
Vilazodone—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00203	0.00996	CcSEcCtD
Vilazodone—Arthralgia—Rosuvastatin—atherosclerosis	0.00184	0.00904	CcSEcCtD
Vilazodone—Mental disorder—Ezetimibe—atherosclerosis	0.00181	0.00888	CcSEcCtD
Vilazodone—Flatulence—Lovastatin—atherosclerosis	0.00181	0.00886	CcSEcCtD
Vilazodone—Malnutrition—Ezetimibe—atherosclerosis	0.0018	0.00882	CcSEcCtD
Vilazodone—Dysgeusia—Lovastatin—atherosclerosis	0.0018	0.00881	CcSEcCtD
Vilazodone—Flatulence—Ezetimibe—atherosclerosis	0.00177	0.00869	CcSEcCtD
Vilazodone—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00173	0.00849	CcSEcCtD
Vilazodone—Vision blurred—Lovastatin—atherosclerosis	0.00173	0.00848	CcSEcCtD
Vilazodone—Mental disorder—Simvastatin—atherosclerosis	0.00173	0.00847	CcSEcCtD
Vilazodone—Tremor—Lovastatin—atherosclerosis	0.00172	0.00843	CcSEcCtD
Vilazodone—Eye disorder—Niacin—atherosclerosis	0.00169	0.00829	CcSEcCtD
Vilazodone—Flatulence—Simvastatin—atherosclerosis	0.00169	0.00829	CcSEcCtD
Vilazodone—Dysgeusia—Simvastatin—atherosclerosis	0.00168	0.00824	CcSEcCtD
Vilazodone—Cardiac disorder—Pravastatin—atherosclerosis	0.00166	0.00811	CcSEcCtD
Vilazodone—Vision blurred—Simvastatin—atherosclerosis	0.00162	0.00793	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00161	0.00789	CcSEcCtD
Vilazodone—Tremor—Simvastatin—atherosclerosis	0.00161	0.00788	CcSEcCtD
Vilazodone—Insomnia—Rosuvastatin—atherosclerosis	0.0016	0.00783	CcSEcCtD
Vilazodone—Palpitations—Ezetimibe—atherosclerosis	0.00159	0.0078	CcSEcCtD
Vilazodone—Paraesthesia—Rosuvastatin—atherosclerosis	0.00159	0.00778	CcSEcCtD
Vilazodone—Malnutrition—Niacin—atherosclerosis	0.00158	0.00773	CcSEcCtD
Vilazodone—Arthralgia—Lovastatin—atherosclerosis	0.00156	0.00766	CcSEcCtD
Vilazodone—Dyspepsia—Rosuvastatin—atherosclerosis	0.00156	0.00762	CcSEcCtD
Vilazodone—Flatulence—Niacin—atherosclerosis	0.00155	0.00761	CcSEcCtD
Vilazodone—Arthralgia—Ezetimibe—atherosclerosis	0.00153	0.00751	CcSEcCtD
Vilazodone—Nervousness—Niacin—atherosclerosis	0.00153	0.0075	CcSEcCtD
Vilazodone—Flatulence—Pravastatin—atherosclerosis	0.00153	0.00749	CcSEcCtD
Vilazodone—Dry mouth—Lovastatin—atherosclerosis	0.00153	0.00749	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00152	0.00746	CcSEcCtD
Vilazodone—Dysgeusia—Pravastatin—atherosclerosis	0.00152	0.00745	CcSEcCtD
Vilazodone—Nervousness—Pravastatin—atherosclerosis	0.00151	0.00739	CcSEcCtD
Vilazodone—Dry mouth—Ezetimibe—atherosclerosis	0.0015	0.00735	CcSEcCtD
Vilazodone—Vision blurred—Niacin—atherosclerosis	0.00149	0.00728	CcSEcCtD
Vilazodone—Vision blurred—Pravastatin—atherosclerosis	0.00146	0.00717	CcSEcCtD
Vilazodone—Arthralgia—Simvastatin—atherosclerosis	0.00146	0.00716	CcSEcCtD
Vilazodone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00146	0.00714	CcSEcCtD
Vilazodone—Tremor—Pravastatin—atherosclerosis	0.00145	0.00713	CcSEcCtD
Vilazodone—Nervous system disorder—Ezetimibe—atherosclerosis	0.00144	0.00706	CcSEcCtD
Vilazodone—Skin disorder—Ezetimibe—atherosclerosis	0.00143	0.00699	CcSEcCtD
Vilazodone—Palpitations—Niacin—atherosclerosis	0.00139	0.00683	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00137	0.00669	CcSEcCtD
Vilazodone—Insomnia—Lovastatin—atherosclerosis	0.00136	0.00664	CcSEcCtD
Vilazodone—Paraesthesia—Lovastatin—atherosclerosis	0.00135	0.00659	CcSEcCtD
Vilazodone—Arthralgia—Niacin—atherosclerosis	0.00134	0.00658	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00134	0.00656	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00133	0.00653	CcSEcCtD
Vilazodone—Insomnia—Ezetimibe—atherosclerosis	0.00133	0.00651	CcSEcCtD
Vilazodone—Arthralgia—Pravastatin—atherosclerosis	0.00132	0.00648	CcSEcCtD
Vilazodone—Paraesthesia—Ezetimibe—atherosclerosis	0.00132	0.00647	CcSEcCtD
Vilazodone—Dyspepsia—Lovastatin—atherosclerosis	0.00132	0.00646	CcSEcCtD
Vilazodone—Dry mouth—Niacin—atherosclerosis	0.00131	0.00643	CcSEcCtD
Vilazodone—Decreased appetite—Lovastatin—atherosclerosis	0.0013	0.00638	CcSEcCtD
Vilazodone—Dyspepsia—Ezetimibe—atherosclerosis	0.00129	0.00634	CcSEcCtD
Vilazodone—Fatigue—Lovastatin—atherosclerosis	0.00129	0.00633	CcSEcCtD
Vilazodone—Decreased appetite—Ezetimibe—atherosclerosis	0.00128	0.00626	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00128	0.00626	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00127	0.00622	CcSEcCtD
Vilazodone—Asthenia—Rosuvastatin—atherosclerosis	0.00127	0.00621	CcSEcCtD
Vilazodone—Insomnia—Simvastatin—atherosclerosis	0.00127	0.00621	CcSEcCtD
Vilazodone—Fatigue—Ezetimibe—atherosclerosis	0.00127	0.00621	CcSEcCtD
Vilazodone—Paraesthesia—Simvastatin—atherosclerosis	0.00126	0.00617	CcSEcCtD
Vilazodone—Skin disorder—Niacin—atherosclerosis	0.00125	0.00612	CcSEcCtD
Vilazodone—Hyperhidrosis—Niacin—atherosclerosis	0.00124	0.00609	CcSEcCtD
Vilazodone—Feeling abnormal—Lovastatin—atherosclerosis	0.00123	0.00605	CcSEcCtD
Vilazodone—Dyspepsia—Simvastatin—atherosclerosis	0.00123	0.00604	CcSEcCtD
Vilazodone—Hyperhidrosis—Pravastatin—atherosclerosis	0.00122	0.006	CcSEcCtD
Vilazodone—Decreased appetite—Simvastatin—atherosclerosis	0.00122	0.00597	CcSEcCtD
Vilazodone—Feeling abnormal—Ezetimibe—atherosclerosis	0.00121	0.00593	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00121	0.00593	CcSEcCtD
Vilazodone—Diarrhoea—Rosuvastatin—atherosclerosis	0.00121	0.00593	CcSEcCtD
Vilazodone—Fatigue—Simvastatin—atherosclerosis	0.00121	0.00592	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00117	0.00574	CcSEcCtD
Vilazodone—Dizziness—Rosuvastatin—atherosclerosis	0.00117	0.00573	CcSEcCtD
Vilazodone—Insomnia—Niacin—atherosclerosis	0.00116	0.0057	CcSEcCtD
Vilazodone—Paraesthesia—Niacin—atherosclerosis	0.00116	0.00566	CcSEcCtD
Vilazodone—Feeling abnormal—Simvastatin—atherosclerosis	0.00115	0.00566	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00115	0.00566	CcSEcCtD
Vilazodone—Insomnia—Pravastatin—atherosclerosis	0.00115	0.00561	CcSEcCtD
Vilazodone—Somnolence—Niacin—atherosclerosis	0.00114	0.0056	CcSEcCtD
Vilazodone—Paraesthesia—Pravastatin—atherosclerosis	0.00114	0.00557	CcSEcCtD
Vilazodone—Dyspepsia—Niacin—atherosclerosis	0.00113	0.00555	CcSEcCtD
Vilazodone—Decreased appetite—Niacin—atherosclerosis	0.00112	0.00548	CcSEcCtD
Vilazodone—Dyspepsia—Pravastatin—atherosclerosis	0.00112	0.00546	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Niacin—atherosclerosis	0.00111	0.00544	CcSEcCtD
Vilazodone—Decreased appetite—Pravastatin—atherosclerosis	0.0011	0.0054	CcSEcCtD
Vilazodone—Fatigue—Pravastatin—atherosclerosis	0.00109	0.00535	CcSEcCtD
Vilazodone—Asthenia—Lovastatin—atherosclerosis	0.00107	0.00527	CcSEcCtD
Vilazodone—Asthenia—Ezetimibe—atherosclerosis	0.00105	0.00517	CcSEcCtD
Vilazodone—Nausea—Rosuvastatin—atherosclerosis	0.00105	0.00515	CcSEcCtD
Vilazodone—Feeling abnormal—Pravastatin—atherosclerosis	0.00104	0.00512	CcSEcCtD
Vilazodone—Diarrhoea—Lovastatin—atherosclerosis	0.00103	0.00502	CcSEcCtD
Vilazodone—Asthenia—Simvastatin—atherosclerosis	0.00101	0.00493	CcSEcCtD
Vilazodone—Diarrhoea—Ezetimibe—atherosclerosis	0.00101	0.00493	CcSEcCtD
Vilazodone—Dizziness—Lovastatin—atherosclerosis	0.000991	0.00485	CcSEcCtD
Vilazodone—Dizziness—Ezetimibe—atherosclerosis	0.000972	0.00476	CcSEcCtD
Vilazodone—Diarrhoea—Simvastatin—atherosclerosis	0.000959	0.0047	CcSEcCtD
Vilazodone—Vomiting—Lovastatin—atherosclerosis	0.000953	0.00467	CcSEcCtD
Vilazodone—Vomiting—Ezetimibe—atherosclerosis	0.000934	0.00458	CcSEcCtD
Vilazodone—Dizziness—Simvastatin—atherosclerosis	0.000927	0.00454	CcSEcCtD
Vilazodone—Asthenia—Niacin—atherosclerosis	0.000923	0.00452	CcSEcCtD
Vilazodone—Asthenia—Pravastatin—atherosclerosis	0.000909	0.00445	CcSEcCtD
Vilazodone—Vomiting—Simvastatin—atherosclerosis	0.000891	0.00437	CcSEcCtD
Vilazodone—Nausea—Lovastatin—atherosclerosis	0.00089	0.00436	CcSEcCtD
Vilazodone—Diarrhoea—Niacin—atherosclerosis	0.00088	0.00431	CcSEcCtD
Vilazodone—Nausea—Ezetimibe—atherosclerosis	0.000873	0.00428	CcSEcCtD
Vilazodone—Diarrhoea—Pravastatin—atherosclerosis	0.000867	0.00425	CcSEcCtD
Vilazodone—Dizziness—Niacin—atherosclerosis	0.000851	0.00417	CcSEcCtD
Vilazodone—Dizziness—Pravastatin—atherosclerosis	0.000838	0.0041	CcSEcCtD
Vilazodone—Nausea—Simvastatin—atherosclerosis	0.000832	0.00408	CcSEcCtD
Vilazodone—Vomiting—Niacin—atherosclerosis	0.000818	0.00401	CcSEcCtD
Vilazodone—Vomiting—Pravastatin—atherosclerosis	0.000806	0.00395	CcSEcCtD
Vilazodone—Nausea—Niacin—atherosclerosis	0.000764	0.00374	CcSEcCtD
Vilazodone—Nausea—Pravastatin—atherosclerosis	0.000753	0.00369	CcSEcCtD
Vilazodone—HTR1A—Signaling Pathways—CNR2—atherosclerosis	4.69e-05	0.000512	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL8—atherosclerosis	4.69e-05	0.000512	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MMP3—atherosclerosis	4.68e-05	0.000511	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTM1—atherosclerosis	4.66e-05	0.000509	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KNG1—atherosclerosis	4.64e-05	0.000506	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PRKCG—atherosclerosis	4.63e-05	0.000505	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—UTS2—atherosclerosis	4.62e-05	0.000504	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AGTR1—atherosclerosis	4.61e-05	0.000503	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—LPL—atherosclerosis	4.58e-05	0.000499	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GPX1—atherosclerosis	4.46e-05	0.000487	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EDN1—atherosclerosis	4.45e-05	0.000486	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CX3CR1—atherosclerosis	4.43e-05	0.000484	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASR—atherosclerosis	4.43e-05	0.000484	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL5—atherosclerosis	4.42e-05	0.000482	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CD36—atherosclerosis	4.35e-05	0.000474	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CX3CL1—atherosclerosis	4.35e-05	0.000474	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—IL6—atherosclerosis	4.33e-05	0.000472	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	4.32e-05	0.000471	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—EDN1—atherosclerosis	4.31e-05	0.00047	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CCL5—atherosclerosis	4.27e-05	0.000466	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCG1—atherosclerosis	4.26e-05	0.000464	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PRKCG—atherosclerosis	4.2e-05	0.000458	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VWF—atherosclerosis	4.18e-05	0.000456	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOC3—atherosclerosis	4.16e-05	0.000454	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LDLR—atherosclerosis	4.13e-05	0.000451	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CNR2—atherosclerosis	4.12e-05	0.00045	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—MTHFR—atherosclerosis	4.12e-05	0.000449	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL8—atherosclerosis	4.12e-05	0.000449	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MMP3—atherosclerosis	4.11e-05	0.000449	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AGT—atherosclerosis	4.07e-05	0.000444	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PRKCG—atherosclerosis	4.06e-05	0.000443	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLTP—atherosclerosis	4.06e-05	0.000443	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PPARA—atherosclerosis	4.04e-05	0.000441	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL3—atherosclerosis	4.04e-05	0.00044	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LCAT—atherosclerosis	4e-05	0.000437	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—FABP4—atherosclerosis	4e-05	0.000437	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA4—atherosclerosis	3.93e-05	0.000428	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AGT—atherosclerosis	3.92e-05	0.000427	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EDN1—atherosclerosis	3.91e-05	0.000427	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL5—atherosclerosis	3.88e-05	0.000423	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NCF1—atherosclerosis	3.87e-05	0.000422	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP7A1—atherosclerosis	3.86e-05	0.000421	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—APOE—atherosclerosis	3.84e-05	0.000418	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CAV1—atherosclerosis	3.8e-05	0.000415	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—APOA1—atherosclerosis	3.79e-05	0.000414	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—F2—atherosclerosis	3.76e-05	0.00041	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AGT—atherosclerosis	3.7e-05	0.000403	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	3.69e-05	0.000402	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VWF—atherosclerosis	3.67e-05	0.000401	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOC3—atherosclerosis	3.65e-05	0.000398	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EDNRA—atherosclerosis	3.65e-05	0.000398	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCR2—atherosclerosis	3.65e-05	0.000398	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CYBA—atherosclerosis	3.63e-05	0.000396	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LDLR—atherosclerosis	3.63e-05	0.000396	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CG—atherosclerosis	3.6e-05	0.000393	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AGT—atherosclerosis	3.58e-05	0.00039	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP27A1—atherosclerosis	3.57e-05	0.000389	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PARP1—atherosclerosis	3.56e-05	0.000388	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PLAT—atherosclerosis	3.56e-05	0.000388	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GHRL—atherosclerosis	3.56e-05	0.000388	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL3—atherosclerosis	3.54e-05	0.000387	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LTA4H—atherosclerosis	3.52e-05	0.000384	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG8—atherosclerosis	3.52e-05	0.000384	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CG—atherosclerosis	3.46e-05	0.000378	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—F2—atherosclerosis	3.42e-05	0.000373	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NCF1—atherosclerosis	3.39e-05	0.00037	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	3.38e-05	0.000369	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALOX15—atherosclerosis	3.38e-05	0.000369	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA2—atherosclerosis	3.38e-05	0.000369	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	3.38e-05	0.000369	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PPARG—atherosclerosis	3.34e-05	0.000364	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCG5—atherosclerosis	3.34e-05	0.000364	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—F2—atherosclerosis	3.3e-05	0.00036	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—INS—atherosclerosis	3.28e-05	0.000357	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CG—atherosclerosis	3.27e-05	0.000357	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AGT—atherosclerosis	3.25e-05	0.000354	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LPA—atherosclerosis	3.23e-05	0.000352	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCR2—atherosclerosis	3.21e-05	0.00035	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EDNRA—atherosclerosis	3.21e-05	0.00035	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CYBA—atherosclerosis	3.19e-05	0.000348	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	3.16e-05	0.000345	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—BGN—atherosclerosis	3.12e-05	0.000341	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PLAT—atherosclerosis	3.12e-05	0.000341	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PARP1—atherosclerosis	3.12e-05	0.000341	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GHRL—atherosclerosis	3.12e-05	0.000341	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KNG1—atherosclerosis	3.12e-05	0.000341	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AGTR1—atherosclerosis	3.1e-05	0.000339	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA5—atherosclerosis	3.09e-05	0.000337	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL2—atherosclerosis	3.05e-05	0.000332	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PLG—atherosclerosis	3.02e-05	0.00033	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALB—atherosclerosis	3e-05	0.000328	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—F2—atherosclerosis	3e-05	0.000327	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	2.98e-05	0.000325	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALOX5—atherosclerosis	2.88e-05	0.000314	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NOS3—atherosclerosis	2.87e-05	0.000313	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	2.87e-05	0.000313	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SOCS3—atherosclerosis	2.86e-05	0.000312	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG1—atherosclerosis	2.78e-05	0.000304	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP3—atherosclerosis	2.77e-05	0.000302	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF2—atherosclerosis	2.75e-05	0.0003	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KNG1—atherosclerosis	2.74e-05	0.000299	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AGTR1—atherosclerosis	2.73e-05	0.000297	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOB—atherosclerosis	2.67e-05	0.000292	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL2—atherosclerosis	2.67e-05	0.000292	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PLG—atherosclerosis	2.66e-05	0.00029	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—atherosclerosis	2.65e-05	0.000289	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EDN1—atherosclerosis	2.63e-05	0.000287	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—atherosclerosis	2.63e-05	0.000287	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LCAT—atherosclerosis	2.62e-05	0.000285	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—FABP4—atherosclerosis	2.62e-05	0.000285	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL5—atherosclerosis	2.61e-05	0.000285	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.58e-05	0.000281	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA4—atherosclerosis	2.57e-05	0.00028	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LIPC—atherosclerosis	2.56e-05	0.00028	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LPL—atherosclerosis	2.55e-05	0.000279	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOC3—atherosclerosis	2.55e-05	0.000278	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LDLR—atherosclerosis	2.53e-05	0.000276	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.52e-05	0.000275	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SOCS3—atherosclerosis	2.52e-05	0.000274	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	2.48e-05	0.000271	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CETP—atherosclerosis	2.47e-05	0.00027	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP3—atherosclerosis	2.43e-05	0.000265	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF2—atherosclerosis	2.42e-05	0.000264	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SPP1—atherosclerosis	2.42e-05	0.000264	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	2.41e-05	0.000263	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.37e-05	0.000258	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOB—atherosclerosis	2.35e-05	0.000256	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.33e-05	0.000254	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	2.33e-05	0.000254	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EDN1—atherosclerosis	2.31e-05	0.000252	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL5—atherosclerosis	2.29e-05	0.00025	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LPL—atherosclerosis	2.24e-05	0.000245	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	2.24e-05	0.000244	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.24e-05	0.000244	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.21e-05	0.000241	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.21e-05	0.000241	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA2—atherosclerosis	2.21e-05	0.000241	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.21e-05	0.000241	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AGT—atherosclerosis	2.18e-05	0.000238	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.18e-05	0.000238	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PRKCG—atherosclerosis	2.18e-05	0.000238	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—atherosclerosis	2.14e-05	0.000233	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOE—atherosclerosis	2.14e-05	0.000233	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SPP1—atherosclerosis	2.12e-05	0.000232	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CAV1—atherosclerosis	2.12e-05	0.000231	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOA1—atherosclerosis	2.12e-05	0.000231	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	2.11e-05	0.000231	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LPA—atherosclerosis	2.11e-05	0.00023	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ESR1—atherosclerosis	2.04e-05	0.000223	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—BGN—atherosclerosis	2.04e-05	0.000223	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA5—atherosclerosis	2.02e-05	0.000221	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—F2—atherosclerosis	2.02e-05	0.00022	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.99e-05	0.000217	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PDGFB—atherosclerosis	1.96e-05	0.000214	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.95e-05	0.000212	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	1.93e-05	0.000211	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AGT—atherosclerosis	1.92e-05	0.000209	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.88e-05	0.000205	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—atherosclerosis	1.88e-05	0.000205	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOE—atherosclerosis	1.88e-05	0.000205	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CAV1—atherosclerosis	1.86e-05	0.000203	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOA1—atherosclerosis	1.86e-05	0.000203	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	1.85e-05	0.000202	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—INS—atherosclerosis	1.83e-05	0.000199	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL2—atherosclerosis	1.8e-05	0.000196	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ESR1—atherosclerosis	1.79e-05	0.000196	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—F2—atherosclerosis	1.77e-05	0.000193	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—atherosclerosis	1.77e-05	0.000193	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.71e-05	0.000187	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	1.7e-05	0.000185	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.69e-05	0.000184	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	1.68e-05	0.000183	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LIPC—atherosclerosis	1.68e-05	0.000183	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOC3—atherosclerosis	1.67e-05	0.000182	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LDLR—atherosclerosis	1.65e-05	0.000181	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOB—atherosclerosis	1.64e-05	0.000179	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	1.62e-05	0.000177	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CETP—atherosclerosis	1.62e-05	0.000176	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—INS—atherosclerosis	1.61e-05	0.000175	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—atherosclerosis	1.6e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.59e-05	0.000174	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.58e-05	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LPL—atherosclerosis	1.56e-05	0.000171	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.55e-05	0.000169	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.55e-05	0.000169	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPX1—atherosclerosis	1.53e-05	0.000166	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CD36—atherosclerosis	1.49e-05	0.000162	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.47e-05	0.000161	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.46e-05	0.000159	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	1.42e-05	0.000155	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.41e-05	0.000154	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.41e-05	0.000154	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARA—atherosclerosis	1.38e-05	0.000151	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.37e-05	0.00015	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.35e-05	0.000148	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AGT—atherosclerosis	1.34e-05	0.000146	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—atherosclerosis	1.32e-05	0.000144	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOE—atherosclerosis	1.31e-05	0.000143	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.3e-05	0.000142	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CAV1—atherosclerosis	1.3e-05	0.000142	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA1—atherosclerosis	1.3e-05	0.000141	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.29e-05	0.00014	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.27e-05	0.000139	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.25e-05	0.000136	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.25e-05	0.000136	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.25e-05	0.000136	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.21e-05	0.000132	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.19e-05	0.00013	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.18e-05	0.000129	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.16e-05	0.000126	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.14e-05	0.000125	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARG—atherosclerosis	1.14e-05	0.000125	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.13e-05	0.000123	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—INS—atherosclerosis	1.12e-05	0.000122	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.12e-05	0.000122	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.12e-05	0.000122	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.1e-05	0.00012	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.1e-05	0.000119	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.09e-05	0.000119	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOB—atherosclerosis	1.07e-05	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.06e-05	0.000116	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.04e-05	0.000114	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—atherosclerosis	1.03e-05	0.000112	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LPL—atherosclerosis	1.02e-05	0.000112	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	0.000111	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—atherosclerosis	1e-05	0.00011	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX1—atherosclerosis	9.98e-06	0.000109	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—atherosclerosis	9.82e-06	0.000107	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CD36—atherosclerosis	9.71e-06	0.000106	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK3—atherosclerosis	9.59e-06	0.000105	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—atherosclerosis	9.31e-06	0.000102	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—atherosclerosis	9.21e-06	0.0001	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARA—atherosclerosis	9.03e-06	9.85e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—atherosclerosis	8.98e-06	9.8e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AGT—atherosclerosis	8.75e-06	9.54e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOE—atherosclerosis	8.57e-06	9.35e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CAV1—atherosclerosis	8.49e-06	9.26e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA1—atherosclerosis	8.47e-06	9.24e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—atherosclerosis	7.99e-06	8.71e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	7.73e-06	8.44e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARG—atherosclerosis	7.47e-06	8.14e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	7.37e-06	8.04e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—INS—atherosclerosis	7.32e-06	7.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—atherosclerosis	7.01e-06	7.65e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—atherosclerosis	6.71e-06	7.32e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—atherosclerosis	6.47e-06	7.06e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—atherosclerosis	6.42e-06	7e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—atherosclerosis	5.87e-06	6.41e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—atherosclerosis	4.51e-06	4.92e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—atherosclerosis	2.95e-06	3.22e-05	CbGpPWpGaD
